ClinicalTrials.gg

Autoimmune Diseases clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 803 studies for Autoimmune Diseases across more than 10 countries. 272 are recruiting or about to start. 219 of them are mainly about Autoimmune Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 41 narrower conditions too, such as Diabetes Mellitus, Type 1: 15,753 studies, 3,345 open.

ClinicalTrials.gov finds 15,606 studies for Autoimmune Diseases. How that becomes 802 here

This page counts the studies the registry files under Autoimmune Diseases, and those it files under no condition that list Autoimmune Diseasesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 15,606Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −14,438Filed under a narrower condition, counted on its own pageDiabetes Mellitus, Type 1 3,509 · Arthritis, Rheumatoid 3,201 · Multiple Sclerosis 3,078 · Lupus Erythematosus, Systemic 956 · Purpura, Thrombocytopenic, Idiopathic 450 · Arthritis, Juvenile 311 · 34 more
  3. −13List Autoimmune Diseases as a condition, but the registry did not file them under itMost often written as “Systemic Autoimmune Diseases” (4), “Raynaud's Disease Secondary to Autoimmune Disease” (1), and “Raynaud's Disease Secondary to Other Autoimmune Disease” (1). The registry filed them under other conditions only, most often Raynaud Disease (2) and Scleroderma, Diffuse (2).
  4. −353Match it another way32 name it in the title, 7 in a keyword, and 314 by a synonym or other text the search reads.
  5. 802The count on this page14 of them list Autoimmune Diseases in their own words; the registry filed them under no condition.

Status

Completed
347
Recruiting
195
Not yet recruiting
63
Status unknown
62
Terminated
56
Active, not recruiting
35

Phase

Phase 1
181
Phase 2
178
Phase 3
66
Early Phase 1
50
Phase 4
26

Where

United States
341
China
125
France
96
Germany
75
United Kingdom
73
Spain
66

Who develops what

Add Autoimmune Diseases to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 60 programs from 46 companies, 22 with this as their studies’ main aim; 7 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Changchun GeneScience Pharmaceutical and Grit Biotechnology here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Immunosuppressive AgentsRecent, limited
Evidence
  • NCT06342960 · Kyverna Therapeutics · Phase 2 · background · “Standard lymphodepletion regimen” · registered Mar 2024
  • NCT06384976 · Kyverna Therapeutics · Phase 2 · live · background · “Standard lymphodepletion regimen” · registered Nov 2023
  • NCT06193889 · Kyverna Therapeutics · Phase 3 · live · background · “Standard lymphodepletion regimen” · registered Oct 2023
  • NCT06400303 · Kyverna Therapeutics · Phase 2 · background · “Standard lymphodepletion regimen” · registered Aug 2023
  • NCT05938725 · Kyverna Therapeutics · Phase 2 · background · “Standard lymphodepletion regimen” · registered Oct 2022
—15 studies
MethotrexateEarlier only
Evidence
  • NCT03239600 · GlaxoSmithKline · Phase 2 · background · “Methotrexate” · registered Jun 2017
  • NCT01004432 · Johnson & Johnson · Phase 3 · background · “Methotrexate (MTX)” · registered Oct 2009
  • NCT00950989 · Amgen · Phase 2 · background · “Methotrexate” · registered Jul 2009
Hoffmann-La Roche28% of its industry studiesUS: off-patent, 21 generics marketedEU: Nordic Group B.V. (EMA 2016) + 1 other00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
mezagitamab☆ Track2 live phase-3 studies: NCT06722235, NCT06948318Takeda

The 1 in phase 3 with the nearest primary completion, of 60 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Immunoglobulins, Intravenous · kedrion s p a · Phase 3 named, not the main aimNCT07059000 A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) — primary endpoint: Rate of subjects with response (R) · 40 enrolled
  • 13 Mar 2027 est.sibeprenlimab · Otsuka Holdings Co., Ltd. · Phase 2 main aimNCT06928142 A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's — primary endpoint: Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) score · 83 enrolled
  • May 2027 est.tibulizumab · Zura Bio Inc · Phase 2 registry mapping onlyNCT06843239 Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) — primary endpoint: [Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks · 80 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Autoimmune Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 6 open · Alkylating agents 3 open · Corticosteroids 2 open · Calcineurin inhibitors 2 open · GLP-1 receptor agonists 2 open

Coming up

81studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger. 55 (28%) take children under 18. 6 (3%) are for women only and 5 (3%) for men only; 36 (18%) take healthy volunteers.

Recruiting studies that take each age, of 195
AgeWomenMen
1044 (23%)44 (23%)
18180 (92%)178 (91%)
30181 (93%)179 (92%)
40181 (93%)180 (92%)
50180 (92%)181 (93%)
65172 (88%)173 (89%)
75127 (65%)128 (66%)
85108 (55%)108 (55%)

Across all 803 studies, recruiting or not: 46% stop at 75 or younger and 31% at 65; 25% take children; 5% are for women only and 2% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Autoimmune Diseases studies take

Of 95 phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 123 mo9–36 · 95 studies13 mo9–32 · 69 studies—
Phase 255 mo34–100 · 60 studies—76 mo52–114 · 31 studies
Phase 348 mo36–84 · 29 studies——
Interventional, no phase31 mo15–62 · 87 studies—35 mo16–62 · 78 studies
Observational121 mo41–309 · 92 studies—121 mo41–309 · 77 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 803. Browse all 803 → or search them.